{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:03:52Z","timestamp":1784541832088,"version":"3.55.0"},"reference-count":52,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15693","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:30:16Z","timestamp":1781155816000},"page":"1-18","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a predictive model of pathological complete response combined with MRI and tumor indicators for HER2\u2011positive breast cancer after neoadjuvant targeted therapy"],"prefix":"10.3892","volume":"32","author":[{"given":"Keying","family":"Zhu","sequence":"first","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeying","family":"Li","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Liao","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changan","family":"Wang","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Guo","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyin","family":"Tang","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedian","family":"Chen","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankui","family":"Wang","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Nie","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Yunnan Key Laboratory of Breast Cancer Precision Medicine, Department of Breast Surgery, Breast Cancer Center of The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Peking University Cancer Hospital Yunnan Hospital, Kunming, Yunnan 650118, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"key20260720122030_b1-ol-32-2-15693","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260720122030_b2-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"key20260720122030_b3-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00108-018-0398-1","article-title":"The 20-year results of 5-year hormone therapy in breast cancer: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","volume":"56","author":"Traub","year":"2018","journal-title":"Internist (Berl)"},{"key":"key20260720122030_b4-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive Meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20260720122030_b5-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"key20260720122030_b6-ol-32-2-15693","first-page":"8","article-title":"Evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: Correlation with molecular phenotype","volume":"54","author":"Blanco","year":"2021","journal-title":"Rev Esp Patol"},{"key":"key20260720122030_b7-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.breast.2022.01.006","article-title":"Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer","volume":"62","author":"Harbeck","year":"2022","journal-title":"Breast"},{"key":"key20260720122030_b8-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20260720122030_b9-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20260720122030_b10-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20260720122030_b11-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s00330-015-3886-x","article-title":"Combined reading of contrast enhanced and diffusion weighted magnetic resonance imaging by using a simple sum score","volume":"26","author":"Baltzer","year":"2016","journal-title":"Eur Radiol"},{"key":"key20260720122030_b12-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-017-4254-0","article-title":"MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy","volume":"164","author":"van Ramshorst","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"key20260720122030_b13-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1148\/radiol.10092021","article-title":"Diffusion-weighted MR imaging: Pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer","volume":"257","author":"Park","year":"2010","journal-title":"Radiology"},{"key":"key20260720122030_b14-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3348\/kjr.2018.19.4.682","article-title":"Early prediction of response to neoadjuvant chemotherapy using dynamic Contrast-enhanced MRI and ultrasound in breast cancer","volume":"19","author":"Kim","year":"2018","journal-title":"Korean J Radiol"},{"key":"key20260720122030_b15-ol-32-2-15693","first-page":"1","article-title":"Biomarkers in breast cancer: Where are we and where are we going?","volume":"71","author":"Duffy","year":"2015","journal-title":"Adv Clin Chem"},{"key":"key20260720122030_b16-ol-32-2-15693","first-page":"CD011134","article-title":"Blood CEA levels for detecting recurrent colorectal cancer","volume":"2015","author":"Nicholson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key20260720122030_b17-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic antigen (CEA) as tumor marker in lung cancer","volume":"76","author":"Grunnet","year":"2012","journal-title":"Lung Cancer"},{"key":"key20260720122030_b18-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12893-022-01667-z","article-title":"Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer","volume":"22","author":"Shibata","year":"2022","journal-title":"BMC Surg"},{"key":"key20260720122030_b19-ol-32-2-15693","first-page":"66","article-title":"Application value of serum tumor markers combined with dynamic detection in the diagnosis and monitoring of breast cancer","volume":"3","author":"Wang","year":"2021","journal-title":"Med Innov China"},{"key":"key20260720122030_b20-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"1066007","DOI":"10.3389\/fonc.2023.1066007","article-title":"Review of the status of neoadjuvant therapy in HER2-positive breast cancer","volume":"13","author":"Dowling","year":"2023","journal-title":"Front Oncol"},{"key":"key20260720122030_b21-ol-32-2-15693","article-title":"AJCC cancer staging manual","author":"Amin","year":"2017","edition":"8th edition"},{"key":"key20260720122030_b22-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"key20260720122030_b23-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"key20260720122030_b24-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/s41467-024-45591-7","article-title":"Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: Final analysis of the randomized phase III PEONY trial","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"key20260720122030_b25-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","article-title":"Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients","volume":"47","author":"Kong","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20260720122030_b26-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12916-015-0472-7","article-title":"Neoadjuvant trials in early breast cancer: Pathological response at surgery and correlation to longer term outcomes-what does it all mean?","volume":"13","author":"Earl","year":"2015","journal-title":"BMC Med"},{"key":"key20260720122030_b27-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"key":"key20260720122030_b28-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20260720122030_b29-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20260720122030_b30-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12957-016-0999-x","article-title":"Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer","volume":"14","author":"Park","year":"2016","journal-title":"World J Surg Oncol"},{"key":"key20260720122030_b31-ol-32-2-15693","first-page":"15","article-title":"Effect of hormone receptor status on Her-2 positive breast cancer","volume":"4","author":"Yang","year":"2022","journal-title":"Chin J Med Sci"},{"key":"key20260720122030_b32-ol-32-2-15693","first-page":"51","article-title":"The Value of TAP Content in Peripheral Blood in Predicting the Efficacy of Neoadjuvant Chemotherapy for Her-2 Positive Breast Cancer","volume":"6","author":"Li","year":"2022","journal-title":"J Jinzhou Med Univ"},{"key":"key20260720122030_b33-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3892\/ijo.2017.3976","article-title":"Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells","volume":"50","author":"McDermott","year":"2017","journal-title":"Int J Oncol"},{"key":"key20260720122030_b34-ol-32-2-15693","first-page":"1722","article-title":"New Mechanism of ER-\u03b136 Mediating Trastuzumab Resistance in Breast Cancer","volume":"27","author":"Luo","year":"2021","journal-title":"Med Recapitulate"},{"key":"key20260720122030_b35-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"103042","DOI":"10.1016\/j.ebiom.2020.103042","article-title":"MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer","volume":"61","author":"Bitencourt","year":"2020","journal-title":"EBioMedicine"},{"key":"key20260720122030_b36-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1590\/1806-9282.20210114","article-title":"Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: A single-center experience","volume":"67","author":"Mermut","year":"2021","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"key20260720122030_b37-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"key20260720122030_b38-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1148\/radiology.211.1.r99ap38101","article-title":"Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions?","volume":"211","author":"Kuhl","year":"1999","journal-title":"Radiology"},{"key":"key20260720122030_b39-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4149\/neo_2017_314","article-title":"Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging","volume":"64","author":"Xu","year":"2017","journal-title":"Neoplasma"},{"key":"key20260720122030_b40-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"8685680","DOI":"10.1155\/2022\/8685680","article-title":"MRI Images-Based evaluation of efficacy of neoadjuvant chemotherapy for breast cancer and its effect on depression and immune function of patients","volume":"2022","author":"Nie","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"key20260720122030_b41-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jmri.26908","article-title":"Diffusion MRI of the breast: Current status and future directions","volume":"52","author":"Iima","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"key20260720122030_b42-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12957-018-1438-y","article-title":"Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: A meta-analysis","volume":"16","author":"Gao","year":"2018","journal-title":"World J Surg Oncol"},{"key":"key20260720122030_b43-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s12032-011-9842-y","article-title":"DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy","volume":"29","author":"Li","year":"2012","journal-title":"Med Oncol"},{"key":"key20260720122030_b44-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1007\/s00330-021-08462-z","article-title":"Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: Comparison between ROI-ADC and whole-lesion-ADC measurements","volume":"32","author":"Hottat","year":"2022","journal-title":"Eur Radiol"},{"key":"key20260720122030_b45-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1148\/radiol.2452061535","article-title":"Tumors in pediatric patients at diffusion-weighted MR imaging: Apparent diffusion coefficient and tumor cellularity","volume":"245","author":"Humphries","year":"2007","journal-title":"Radiology"},{"key":"key20260720122030_b46-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"491","DOI":"10.14740\/jocmr5237","article-title":"The effects of preoperative serum carcinoembryonic antigen, cancer antigen 15-3 and cancer antigen 125 on the prognosis of breast cancer patients with different molecular subtypes","volume":"16","author":"Yilihamu","year":"2024","journal-title":"J Clin Med Res"},{"key":"key20260720122030_b47-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"eaay9040","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer","volume":"375","author":"Crosby","year":"2022","journal-title":"Science"},{"key":"key20260720122030_b48-ol-32-2-15693","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41598-025-30087-1","article-title":"A novel four-serum marker model for early detection and therapeutic monitoring of breast cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"key20260720122030_b49-ol-32-2-15693","first-page":"190","article-title":"Clinical value of combined serum CAl53, CEA, SF, CT and Hcy in the diagnosis of breast cancer","volume":"12","author":"Xu","year":"2020","journal-title":"J Mol Diagn Ther"},{"key":"key20260720122030_b50-ol-32-2-15693","first-page":"13261346","article-title":"Study on diagnostic value of DWI combined with serum carbohydrate antigen 153, 125 and carcinoembryonic antigen in breast cancer","volume":"31","author":"Wu","year":"2021","journal-title":"J Med Imaging"},{"key":"key20260720122030_b51-ol-32-2-15693","first-page":"125","article-title":"The Effect of Trastuzumab in the Treatment of HER-2 Positive Advanced Breast Cancer and its Effect on Serum CEA and CA153 Levels","volume":"34","author":"Liu","year":"2021","journal-title":"J Med Inform"},{"key":"key20260720122030_b52-ol-32-2-15693","first-page":"1","article-title":"A review of prognostic and predictive biomarkers in breast cancer","volume":"23","author":"Tarighati","year":"2023","journal-title":"Clin Exp Med"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:20:41Z","timestamp":1784539241000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15693","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}